Articles tagged with Glaucoma
Researchers discovered a genetic mutation in the THBS1 gene linked to severe childhood glaucoma, which may improve disease screening and treatment. The finding could lead to earlier diagnosis and more targeted therapies for children at risk.
A large UK Biobank study found that poor quality sleep, including insomnia, short/long sleep duration, snoring, and daytime sleepiness, is associated with a heightened risk of developing glaucoma. The study suggests that targeted screening of high-risk groups and sleep intervention may help prevent the disease.
Nanoscope Technologies received a $1.5M NIH SBIR grant to develop gene-agnostic glaucoma therapy utilizing Engineered Mechanosensitive Channels (EMCs). EMCs can autonomously regulate pressure, offering a novel approach to treating Glaucoma.
Researchers found that the APOE4 gene variant associated with Alzheimer's disease decreases risk of glaucoma by blocking a disease cascade. They also identified a potential treatment strategy using Galectin-3 inhibitors to prevent vision loss in mice with glaucoma.
A study of over 26,000 eye care professionals found that those receiving small financial incentives from pharmaceutical companies are up to twice as likely to prescribe brand-name eyedrops for glaucoma. The researchers suggest that frequent exposure to positive messaging about a drug may influence this tendency.
Researchers developed a non-invasive ocular imaging method to detect flavoprotein fluorescence in the eye, indicating mitochondrial oxidative stress. This technique may predict glaucoma progression earlier than current methods, with similar sensitivity to visual field changes.
A new study found that Black patients are six times more likely to have advanced vision loss after a glaucoma diagnosis, highlighting the need for early eye screening in this population. The research analyzed nearly 210,000 participants and used artificial intelligence to identify visual field loss patterns.
A recent study of 7,073 adults found that those with glaucoma had higher cognitive function scores but steeper declines over 18 years. The association was small and unlikely to be clinically meaningful.
Chronic kidney disease and glaucoma have been found to share common risk factors such as diabetes and hypertension, leading to a higher risk of developing both conditions. The study also reveals that patients with glaucoma are more likely to develop chronic kidney disease over time.
Researchers used stem-cell models to uncover hidden genetic markers of glaucoma, a leading cause of permanent blindness. The study identified 312 genetic variants associated with retinal cells and 97 genetic clusters linked to damage caused by glaucoma.
The USPSTF states that primary open-angle glaucoma affects an estimated 2.7 million people in the US, with Black and Hispanic/Latino individuals being disproportionately affected. The organization concludes that screening for this condition is insufficient due to current evidence.
Researchers at OIST Graduate University identified the strip1 gene as essential for keeping retinal ganglion cells alive. The gene suppresses Jun-mediated apoptosis, promoting correct neural circuit formation in the retina. This finding opens promising new avenues for treating diseases like glaucoma.
Researchers have discovered that sigma 1 receptor plays a crucial role in protecting retinal ganglion cells from damage in glaucoma. The protein enables astrocytes to secrete supportive factors for neurons, improving their survival and function.
Researchers at CRCHUM have identified damaged nanotubes connecting pericytes as a major contributor to glaucoma. The study reveals that restoring calcium equilibrium within pericytes can recover vascular and neuronal functions, paving the way for new therapeutic approaches.
A comprehensive study investigates the metabolism of four drugs in rabbit eyes, revealing different enzyme profiles from liver metabolism. The findings provide valuable information for advancing ophthalmic drug development.
A study to investigate stem cell therapy as a potential treatment for glaucoma, the world's second leading cause of blindness, has received $6.7M in NEI funding. The research team will explore ways to make stem cell-derived neurons survive and integrate into the eye.
A new rapid screening test for glaucoma uses infra-red sensors to monitor eye movement, providing accurate results within seconds. The test could help advance early detection of the disease, a leading cause of irreversible blindness, and make it more accessible for national screening programs.
Researchers developed a new protein treatment that prevents glaucoma from forming in mice and reduces pressure in the eyes. The study provides new targets for therapies and aims to develop an injectable treatment for patients.
A Tanzanian study found that laser treatment (SLT) successfully reduced eye pressure to normal levels in 61% of patients after one year, compared to 31% with daily eye drops. SLT may be an affordable alternative for glaucoma care in Africa.
A new study found that toxic fatty acids produced by astrocytes can trigger cell death in damaged neurons, which may contribute to neurodegenerative diseases such as glaucoma and Alzheimer's. Blocking the production of these fatty acids in mice preserved 75% of neurons, suggesting a promising target for treatment.
Researchers found that GLP-1 receptor agonist medications, such as Trulicity and Rybelsus, reduced the risk of glaucoma in diabetic patients by approximately half. The study analyzed data from over 5,000 patients and showed a significant decrease in new glaucoma diagnoses among those taking these medications.
Researchers at University of Illinois Chicago found a potential direct connection between neurodegenerative diseases, such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), glaucoma, and herpesvirus. The study suggests OPTN protein restricts HSV-1 virus spread in cells.
Researchers at Nanyang Technological University and Tan Tock Seng Hospital have developed an AI-powered system to diagnose glaucoma from stereo fundus images, achieving an accuracy of 97% in diagnosing the condition. The automated method could potentially be used in less developed areas where patients lack access to ophthalmologists.
Researchers discovered that CaMKII is a key regulator of the survival of retinal ganglion cells, which process visual information. Gene therapy reactivating CaMKII provided robust protection against vision loss in multiple disease and injury models.
Scientists discover gene therapy that protects optic nerve cells and preserves vision in mouse models of glaucoma. The study suggests a way forward for developing neuroprotective therapies for glaucoma, a leading cause of visual impairment and blindness.
A new genetic test for glaucoma has been found to identify high-risk patients 15 times more effectively than an existing test. The test, which can be performed on a blood or saliva sample, has the potential to detect irreversible vision loss before it occurs.
Women using hormonal contraceptives face a 2-fold higher risk of developing glaucoma compared to non-users. Women with more than four prescriptions for hormonal contraceptives in the past two years had an even higher risk.
A large-scale study found that high caffeine intake may increase the risk of glaucoma by three-fold in individuals with a strong family history. Caffeine consumption above 480mg daily was associated with higher intraocular pressure and increased glaucoma prevalence.
A new AI-powered algorithm, WeakGCSeg, accurately detects and tracks ganglion cells in the retina, surpassing human expertise. This technology enables early diagnosis of neurodegenerative diseases like glaucoma, improving treatment options.
A study analyzing 105 glaucoma trials reveals significant racial and ethnic disparities in clinical trial participation. Minority groups are underrepresented in these trials, which could impact the development of effective treatments for diverse populations.
A team of researchers identified a genetic mutation associated with exfoliation syndrome, the most common cause of glaucoma. The study found that people with exfoliation syndrome are twice as likely to carry damaging mutations in the CYP39A1 protein, which plays a crucial role in cholesterol processing.
Researchers found that about 25% of study participants developed vision loss from glaucoma, a lower rate than expected. The conventional thinking was that most patients with elevated eye pressure should receive treatment due to high costs and potential side effects.
Researchers at NYU Grossman School of Medicine found that citicoline restored optic nerve signals in rats with glaucoma, reducing vision loss and slowing nerve cell decay. The study suggests a new mechanism for treating the condition, which affects over 60 million people worldwide.
Scientists at the University of Cambridge have demonstrated a new approach to gene therapy that may help repair damage caused by neurodegenerative conditions like glaucoma and dementia. The study, published in Science Advances, shows promise for treating chronic degenerative diseases.
Researchers at Flinders University in Australia have found a link between normal-tension glaucoma and cognitive impairment, with patients having this type of glaucoma being more than twice as likely to develop dementia. The study suggests that normal-tension glaucoma may share similar neurodegenerative pathways with dementia.
Research published in British Journal of Ophthalmology found that normal-tension glaucoma is associated with an increased risk of cognitive impairment and possibly dementia. The study suggests that the disease pathways for normal-tension glaucoma may be similar to those for dementia.
A new mobile app, Glaucoma in Perspective, provides glaucoma education in a simple, visual format to help patients and their families understand the potential impact of the condition on their lives. The app covers topics such as visual field tests, eye pressure management, and treatment options.
Researchers at the University of Birmingham have developed a method to measure intraocular pressure using soundwaves, which could help detect glaucoma earlier. This non-invasive technique uses a smartphone to scan people's eyes, prompting early diagnosis and treatment to prevent blindness.
Researchers analyzed genes in over 34,000 people with glaucoma and found 44 new genetic variants that may lead to new treatment targets. The study's findings aim to improve screening and diagnosis of glaucoma, as well as develop new treatments for this incurable eye disease.
Scientists at the University of Birmingham have identified a potential new treatment for open angle glaucoma, a neurodegenerative disease affecting over 70 million people worldwide. ILB has been shown to normalise matrix deposition and lower intraocular pressure in a pre-clinical model, paving the way for anti-fibrotic therapies.
Children who undergo cataract surgery as infants have a 22% risk of developing glaucoma by age 10. Lifelong monitoring is crucial to preventing vision loss due to increased eye pressure and optic nerve damage.
Researchers at Karolinska Institutet have discovered a connection between metabolic disturbance in retinal ganglion cells and high intraocular pressure. Rapamycin and pyruvate treatments showed protective effects in animal and cell models.
A multi-university team identified a family of enzymes called GCK-IV kinases that inhibit robustly neuroprotective while allowing axon regeneration. This finding suggests strong therapeutic possibilities for treating neurodegenerative diseases such as glaucoma and Alzheimer's.
Researchers developed a potential new treatment for glaucoma using a natural, biodegradable hydrogel that opens an alternate pathway for excess fluid to leave the eye. The treatment could provide an efficient alternative to current treatments without daily drops or surgery.
Researchers successfully restored vision in mice by turning back the clock on aged eye cells, reversing vision loss caused by glaucoma. The approach also reversed age-related vision loss in elderly mice, offering promise for treating various age-related diseases in humans.
A new study from City University London suggests that glaucoma eye tests can be accurately performed at home using a tablet-based device called Eyecatcher. The study found high accuracy rates (98%) and adherence, with potential to detect rapidly progressing cases of glaucoma earlier.
A label-free imaging technique has been developed to examine immune cells called macrophages in the retina of healthy humans and patients with glaucoma. Cell density decreased with age in healthy participants, while cell processes moved more quickly and covered a smaller area in patients.
Scientists have used gene therapy to regenerate damaged nerve fibers in the eye, potentially leading to new treatments for glaucoma. The technique stimulated regeneration and protected retinal neurons from cell death, offering hope for protecting vision loss.
A new study aims to replace daily eye drops with a brief low-energy laser procedure to lower eye pressure in glaucoma patients. The trial seeks to improve patients' quality of life and potentially offer a 'drop-free lifetime.'
A team of Pitt professors has received a $1 million NSF grant to create an at-home glaucoma monitoring device that uses acoustic waves to measure intraocular pressure. The project aims to enable patients and non-clinicians to reliably assess IOP, allowing doctors to tailor treatments more effectively.
A team of researchers has discovered a new mechanism that explains why patients with ocular hypertension do not develop glaucoma. They found increased antioxidant capacity and higher levels of omega-3 fatty acid chemical messengers, providing potential resistance to elevated intraocular pressure.
A new study from the University of Missouri School of Medicine found that pre-treatment eye pressure is a key indicator of selective laser trabeculoplasty (SLT) effectiveness in patients with open-angle glaucoma. Patients with higher baseline intraocular pressure achieved larger reductions in pressure after surgery.
Scientists have identified stem cells in the optic nerve that help preserve vision and may lead to new therapeutic strategies for disorders causing blindness. The discovery presents a new theory on why glaucoma develops and provides potential ways to treat this leading cause of blindness in American adults.
A new study by the University of Bradford reveals that people with early-stage glaucoma see contrast in a similar way to those without it, despite measurable vision loss. This underlines the importance of regular eye checks to detect glaucoma before damage is established.
A new study in rodents suggests that star-shaped brain cells called astrocytes may be responsible for killing nerve cells in glaucoma. The study found that increased pressure drove astrocytes to release toxins that killed neurons, highlighting a potential target for treating the disease.
Researchers used a 'disease in a dish' stem cell model to examine the mechanism behind retinal ganglion cell degeneration in glaucoma. The study found that cells from individuals with a genetic risk allele for glaucoma were stalled at an immature stage, making them more vulnerable to degeneration.
Using human stem cell models, researchers identified deficits within cells damaged by glaucoma and found that correcting genetic mutations could slow disease progression. They also discovered dysfunction in autophagy, a process that removes damaged cells, which correlated with neurodegeneration.
A study identified a rare genetic variant in the ANGPTL7 gene that lowers intraocular pressure and significantly reduces the risk of glaucoma. The findings open up new therapeutic possibilities for treating this eye disease.
A new AI-supported test, called DARC, can detect glaucoma progression 18 months earlier than the current gold standard method. The technology involves injecting a fluorescent dye into the bloodstream and illuminating damaged retinal cells using artificial intelligence.
A new study shows a common eye condition, glaucoma, can be successfully treated with gene therapy using a single injection, providing additional treatment options and benefits. Glaucoma affects over 64 million people worldwide and is a leading cause of irreversible blindness.